Self-assessment of voice outcomes after total thyroidectomy using the Voice Handicap Index questionnaire: Results of a prospective multicenter study.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
01 2020
Historique:
received: 31 01 2019
revised: 03 05 2019
accepted: 06 05 2019
pubmed: 19 9 2019
medline: 6 5 2020
entrez: 19 9 2019
Statut: ppublish

Résumé

Voice disorders are frequent after thyroidectomy. We report the long-term voice quality outcomes after thyroidectomy using the voice handicap index self-questionnaire. Eight hundred patients who underwent total thyroidectomy between 2014 and 2017 in 7 French hospitals were prospectively included. All patients filled in voice handicap index questionnaires, preoperatively and 2 and 6 months after surgery. Median (range) voice handicap index scores were significantly increased at month 2 (4 [0; 108]) compared to preoperative values (2 [0; 76]) and were unchanged at month 6 (2 [2; 92]). Clinically significant voice impairment (voice handicap index score difference ≥18 points) was reported in 19.7% at month 2 and 13% at month 6. Thirty-seven (4.6%) had postoperative vocal cord palsy. In patients with vocal cord palsy compared to those without, median voice handicap index scores were increased at month 2 (14 [0; 107] vs 4 [0; 108]; P = .0039), but not at month 6 (5 [0; 92] vs 2 [0; 87]; P = .0702). Clinically significant impairment was reported in 38% vs 19% at month 2 (P = .010), and in 19% vs 13% at month 6 (P = .310). Thyroid weight, postoperative hypocalcemia, vocal cord palsy, and absence of intraoperative neuromonitoring utilization were associated with an increased risk of clinically significant self-perceived voice impairment at month 2. Thyroidectomy impairs patients' voice quality perception in patients with and without vocal cord palsy.

Sections du résumé

BACKGROUND
Voice disorders are frequent after thyroidectomy. We report the long-term voice quality outcomes after thyroidectomy using the voice handicap index self-questionnaire.
METHODS
Eight hundred patients who underwent total thyroidectomy between 2014 and 2017 in 7 French hospitals were prospectively included. All patients filled in voice handicap index questionnaires, preoperatively and 2 and 6 months after surgery.
RESULTS
Median (range) voice handicap index scores were significantly increased at month 2 (4 [0; 108]) compared to preoperative values (2 [0; 76]) and were unchanged at month 6 (2 [2; 92]). Clinically significant voice impairment (voice handicap index score difference ≥18 points) was reported in 19.7% at month 2 and 13% at month 6. Thirty-seven (4.6%) had postoperative vocal cord palsy. In patients with vocal cord palsy compared to those without, median voice handicap index scores were increased at month 2 (14 [0; 107] vs 4 [0; 108]; P = .0039), but not at month 6 (5 [0; 92] vs 2 [0; 87]; P = .0702). Clinically significant impairment was reported in 38% vs 19% at month 2 (P = .010), and in 19% vs 13% at month 6 (P = .310). Thyroid weight, postoperative hypocalcemia, vocal cord palsy, and absence of intraoperative neuromonitoring utilization were associated with an increased risk of clinically significant self-perceived voice impairment at month 2.
CONCLUSION
Thyroidectomy impairs patients' voice quality perception in patients with and without vocal cord palsy.

Identifiants

pubmed: 31526583
pii: S0039-6060(19)30559-8
doi: 10.1016/j.surg.2019.05.090
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-136

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Frédéric Borel (F)

Clinique de Chirurgie Digestive et Endocrinienne, Institut des maladies de l'Appareil Digestif, Hôtel Dieu, CHU Nantes, Place Alexis Ricordeau, Nantes, France.

Christophe Tresallet (C)

Chirurgie Générale, Viscérale et Endocrinienne, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Universités Pierre et Marie Curie (Paris 6), Paris, France.

Antoine Hamy (A)

CHU Angers, Chirurgie digestive et endocrinienne, Angers, France.

Muriel Mathonnet (M)

Chirurgie digestive, générale et endocrinienne, CHU de Limoges, Hôpital Dupuytren, Limoges, France.

Jean-Christophe Lifante (JC)

Chirurgie générale, endocrinienne, digestive et thoracique, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.

Laurent Brunaud (L)

Service de chirurgie digestive, hépato-biliaire, et endocrinienne, CHU Nancy, Hôpital de Brabois, Nancy, France.

Olivier Marret (O)

Chirurgie Vasculaire, CHD Vendée, La Roche sur Yon, France.

Cécile Caillard (C)

Clinique de Chirurgie Digestive et Endocrinienne, Institut des maladies de l'Appareil Digestif, Hôtel Dieu, CHU Nantes, Place Alexis Ricordeau, Nantes, France.

Florent Espitalier (F)

Oto-Rhino- Laryngologie et chirurgie cervico-faciale, Hôtel Dieu, CHU de Nantes, Nantes, France; Université de Nantes, quai de Tourville, Nantes, France.

Delphine Drui (D)

Endocrinologie, Maladies Métaboliques et Nutrition, CHU de Nantes (Hôpital Laennec), Saint-Herblain, France; Institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.

Fabrice Menegaux (F)

Chirurgie Générale, Viscérale et Endocrinienne, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Universités Pierre et Marie Curie (Paris 6), Paris, France.

Jean-Benoit Hardouin (JB)

UMR INSERM 1246-SPHERE, Université de Nantes, Université de Tours, Institut de Recherche en santé 2, Nantes, France; Plateforme de Méthodologie et de Biostatistique, DRCi, CHU de Nantes, Nantes, France.

Claire Blanchard (C)

Clinique de Chirurgie Digestive et Endocrinienne, Institut des maladies de l'Appareil Digestif, Hôtel Dieu, CHU Nantes, Place Alexis Ricordeau, Nantes, France; Université de Nantes, quai de Tourville, Nantes, France; Institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.

Eric Mirallié (E)

Clinique de Chirurgie Digestive et Endocrinienne, Institut des maladies de l'Appareil Digestif, Hôtel Dieu, CHU Nantes, Place Alexis Ricordeau, Nantes, France; Université de Nantes, quai de Tourville, Nantes, France. Electronic address: eric.mirallie@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH